Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination With Pembrolizumab in Subjects With Labyrinthin-Positive Adenocarcinomas

Next Previous
X
Search
Trial Profile

A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination With Pembrolizumab in Subjects With Labyrinthin-Positive Adenocarcinomas

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Labvax-LabyRx Immunologic Therapeutics (Primary) ; Pembrolizumab (Primary) ; Sargramostim (Primary)
  • Indications Adenocarcinoma; Brain metastases; Colon cancer; Non-small cell lung cancer; Ovarian cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use

    • Most Recent Events

    • 10 Oct 2023 Planned number of patients changed from 10 to 77, Interventional study model has been changed to Sequential, Number of treatment arms has been changed to 2, Primary endpoint has been amended and trial focus has now shifted to Ar and Tu, this trial is now a Phase 1/2 study.
    • 10 Oct 2023 Planned End Date changed from 20 Sep 2027 to 1 Jan 2030.
    • 10 Oct 2023 Planned primary completion date changed from 20 Sep 2023 to 1 Jan 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top